Sterilucent

What Sterilucent does

Sterilucent, Inc. is a Minneapolis-based medical device and industrial sterilization company founded in 2004 by David C. Bell. The company developed a vaporized hydrogen peroxide (VHP) decontamination platform centered on its patented iQVHP™ (Intelligent Quality Vaporized Hydrogen Peroxide) technology, which uses continuous in-chamber sensing and real-time adaptive cycle adjustments to deliver a controlled dose of hydrogen peroxide while minimizing material damage and cycle failures. In September 2025, Sterilucent commercially launched its flagship product, the MOXIsmart™ Life Science Processing System, targeting laboratories, pharmaceutical manufacturers, biotechnology firms, and R&D organizations that require validated sterilization cycles compliant with ISO 22441:2022; the system is explicitly not FDA-cleared for healthcare or hospital environments.

Sterilucent operates as a privately held, founder-led company with 1-10 employees, a direct-to-customer go-to-market model (phone and website inquiry), and a single commercial product line. Revenue is generated through capital equipment sales of the MOXIsmart™ system, with likely consumable, service, and validation support attached to the hardware base. Pricing is not publicly disclosed. The company has been funded primarily through non-dilutive grants — initial support from the National Institutes of Health (NIH) and interest from the Department of Defense — followed by angel investor capital, with disclosed funding rounds totaling approximately $7.96M between 2012 and 2015 and no institutional venture or private equity rounds on record.

The company's strategic focus is on the industrial and life sciences sterilization market, where it competes on material compatibility (50+ listed materials including ABS, PEEK, PTFE, stainless steel, titanium, and various polymers), shorter cycle times, lower consumable usage, and reduced cycle aborts relative to traditional VHP systems. The 2025 commercial launch marks the company's transition from two decades of grant-funded R&D to revenue-generating operations, with leadership consisting of founder/CEO David C. Bell and COO Harry Norris.

Name

Sterilucent

Legal name

Sterilucent, Inc.

Website

https://sterilucent.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Sterilucent is a Minneapolis-based private company that develops vaporized hydrogen peroxide decontamination systems for life sciences, pharmaceutical, biotech, and R&D customers, with its MOXIsmart™ platform and patented iQVHP™ technology commercially launched in September 2025.

Ownership category

akta.pro rank

Product category

Sterilization and Decontamination Equipment

NAICS

Irradiation Apparatus Manufacturing (334517), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Industrial Instruments For Measurement, Display, And Control (3823)

akta.pro primary industry

Sterilization Equipment & Systems (Autoclaves, Low-Temp, ETO, H2O2, UV) (HLAHANAA)

akta.pro secondary industry

Sterilization Consumables & Packaging (Wraps, Pouches, Indicators, Trays/Containers) (HLAHANAC)

Keywords

• Hydrogen peroxide sterilization
• Vaporized decontamination systems
• Life science sterilization
• Medical device decontamination
• Cleanroom sterilization equipment

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. Decontamination/Sterilization Equipment Sales: Sterilucent generates revenue from the sale of its MOXIsmart™ Life Science Processing System, a hardware-based decontamination device. The company also likely generates revenue from associated consumables, service contracts, and validation support for industrial and life sciences customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Sterilucent develops and sells the MOXIsmart™ Life Science Processing System, a vaporized hydrogen peroxide (VHP) decontamination device for industrial and life sciences applications. The system uses patented iQVHP™ technology with continuous in-chamber sensing, real-time adaptive cycle adjustments, and smart data analytics to achieve validated sterilization with reduced hydrogen peroxide consumption, fewer failed cycles, and broad material compatibility for sensitive lab equipment.

Product overview

Sterilucent offers a single unified product: the MOXIsmart™ Life Science Processing System with iQVHP™ technology. This system represents an entirely new class of intelligent processor for decontamination applications in life sciences and industrial settings. The product incorporates data-driven intelligence and analytics capabilities that enable adaptive cycle control, continuous in-chamber sensing, and smart chemistry delivery using hydrogen peroxide. The system is designed for laboratories, pharma, and biotech environments requiring validated sterilization cycles with material compatibility across a wide range of sensitive equipment and packaging.

Differentiator

Problem solved

Functional benefit

Brands

• MOXIsmart™: MOXIsmart™ Life Science Processing System featuring patented iQVHP™ technology - an analytics-driven decontamination and sterilization processor for life sciences and industrial settings.

Products and services

• MOXIsmart™ Life Science Processing System The MOXIsmart™ Life Science Processing System is Sterilucent's flagship decontamination and sterilization processor for life science and industrial applications. Featuring patented iQVHP™ (Intelligent Quality Vaporized Hydrogen Peroxide) technology, it provides continuous in-chamber sensing, real-time adaptive cycle adjustments, and smart data analytics to achieve ≥6-log reduction of bacteria and viruses on hard surfaces, validated customizable sterilization cycles (ISO 22441:2022), and compatibility with sensitive lab materials such as plastics, sensors, and packaging. It is intended for laboratories, pharmaceutical manufacturers, biotech firms, and R&D organizations and is not cleared or approved by the U.S. FDA for use in healthcare or hospital environments.

Quantifiable outcome

• Achieves ≥6-log reduction of bacteria and viruses on hard surfaces
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sterilucent-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sterilucent